Products Categories
    Product Certification&
    Enterprise Certification

  • Mr.Xie
    Tel: +86-592-5853819

  • Ms.Serein Yan
    Region Sales Manager
    Tel: +86 0592 5887162

  • Ms.Coco Lv
    Region Sales Manager
    Tel: 0086-592-5881075

  • Ms.Penny Pan
    Region Sales Manager
    Tel: 0086-592-5881087

  • Ms.Shirley Shi
    Region Sales Manager
    Tel: +8613666090822

  • Ms.Denise Lai
    Region Sales Manager
    Tel: 0086-592-5887167

  • Mr.Duncan Deng
    Region Sales Manager
    Tel: +8617750663255

  • Ms.Susie Yan
    Region Sales Manager
    Tel: +8618060975837

  • Ms.Annette Wang
    Region Sales Manager
    Tel: +8615882299465

  • Mobile:+86 13806035118
  • Tel:+86-592-5853819
  • Fax:+86-592-5854960
  • URL:http://www.china-sinoway.com
  • Province/state:fujian
  • City:Xiamen
  • Street:16/F,Huicheng Comm,Complex,No839 XiaHe Rd, Xiamen,China
  • MaxCard:
Home > Products >  factory supply WC,DMF Rivaroxaban

factory supply WC,DMF Rivaroxaban CAS NO.366789-02-8

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,Other
  • Product Details

Keywords

  • Rivaroxaban
  • Apixaban
  • 366789-02-8

Quick Details

  • ProName: factory supply WC,DMF Rivaroxaban
  • CasNo: 366789-02-8
  • Molecular Formula: C22H23ClKN6O
  • Appearance: White crystallization
  • Application: antithrombotic drug
  • DeliveryTime: in two weeks
  • PackAge: 25kg/drum
  • Port: SHANGHAI BEIJING
  • ProductionCapacity: 10 Metric Ton/Day
  • Purity: USP/EP/BP
  • Storage: room temperature
  • Transportation: AIR SEA TRAIN
  • LimitNum: 1 Kilogram

Superiority

We are very compeitive on Rivaroxaban.Our mfr is WC certified for this item with DMF document. 

Product Name: Rivaroxaban
CAS: 366789-02-8
MF: C19H18ClN3O5S
MW: 435.88
EINECS: 685-132-2
Product Categories: Rivaroxaban;Inhibitor;Chiral Reagents;Heterocycles;API;Pharmaceutical raw materials;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Inhibitors
 

Details

Indications and Usage Rivaroxaban is an antithrombotic drug and was developed in a collaboration between the German Bayer Pharmaceuticals and American Johnson company. It is different from the traditional antithrombotic drug heparin in that Rivaroxaban does not need the participation of antithrombin III and can directly antagonize free and bound Xa factors. Heparin requires the effects of antithrombin III, and has no effect on Xa factors in the prothrombin complex. Rivaroxaban is the first oral direct Xa factor inhibitor in the whole world, and it can selectively and competitively inhibit free and bound Da factors as well as prothrombin activity. It uses a dose-dependent method to extend the partial thromboplastin time (PTT) and activated partial thromboplastin time (aPTT) to extend clotting time and lower thrombin genesis. Rivaroxaban has the characteristics of high bioavailability, wide range of target diseases, stable dose-effect relationship, easy oral intake, and low bleeding risk.
Rivaroxaban can also prevent and treat venous thrombosis. It is mainly used clinically to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients following hip and knee replacement surgery. It is also used to prevent patients with nonvalvular atrial fibrillation from cerebral apoplexy and noncentral nervous system embolism, and it can lower the recurrence risk of coronary syndromes.
 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog